Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Buy
68
ETON Quote, Financials, Valuation and Earnings
Last price:
$12.54
Seasonality move
:
-5%
Day range:
$12.00 - $12.63
52-week range:
$3.03 - $13.98
Dividend yield:
0%
P/E ratio:
79.75x
P/S ratio:
9.36x
P/B ratio:
20.21x
Volume:
122.3K
Avg. volume:
269K
1-year change:
172.33%
Market cap:
$323M
Revenue:
$31.6M
EPS (TTM):
-$0.22
Analysts' Opinion
-
Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Eton Pharmaceuticals has an estimated upside of 20% from its current price of $12.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $12.50.
Fair Value
-
According to the consensus of 0 analysts, Eton Pharmaceuticals has 20% upside to fair value with a price target of -- per share.
ETON vs. S&P 500
-
Over the past 5 trading days, Eton Pharmaceuticals has underperformed the S&P 500 by -3.56% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Eton Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eton Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Eton Pharmaceuticals reported revenues of $10.3M.
Earnings Growth
-
Eton Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Eton Pharmaceuticals reported earnings per share of $0.02.
Enterprise value:
306.8M
EV / Invested capital:
15.26x
Price / LTM sales:
9.36x
EV / EBIT:
129.72x
EV / Revenue:
8.85x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1,283.75x
Price / Operating cash flow:
1,357.64x
Enterprise value / EBITDA:
47.44x
Gross Profit (TTM):
$20.6M
Return On Assets:
-16.95%
Net Income Margin (TTM):
-15.81%
Return On Equity:
-35.45%
Return On Invested Capital:
-26.81%
Operating Margin:
4.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $18.8M | $32.8M | $34.7M | $7M | $10.3M | |
| Gross Profit | $13.7M | $23.8M | $20.6M | $4.4M | $6.3M | |
| Operating Income | -$8M | $1.9M | -$5.2M | -$548K | $509K | |
| EBITDA | -$6.9M | $3.5M | -$4.9M | -$357K | $787K | |
| Diluted EPS | -$0.35 | $0.10 | -$0.22 | -$0.02 | $0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.8M | $25.9M | $16.4M | $27.2M | $29.7M | |
| Total Assets | $11.4M | $26.6M | $21.5M | $31.5M | $35.8M | |
| Current Liabilities | $3.2M | $5.4M | $4.7M | $10.4M | $19.7M | |
| Total Liabilities | $10M | $10.9M | $10.3M | $14.6M | $19.9M | |
| Total Equity | $1.4M | $15.7M | $11.2M | $16.9M | $16M | |
| Total Debt | $7M | $6.6M | $6.4M | $5.7M | $4.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.1M | $9.3M | $2.1M | $873K | $3M | |
| Cash From Investing | -$6M | -$12K | -$2.7M | -- | -- | |
| Cash From Financing | -$165K | -$564K | -$1.3M | -$369K | -$385K | |
| Free Cash Flow | -$9.2M | $9.3M | $239K | $873K | $3M | |
ETON
Sector
Market Cap
$323M
$43.9M
Price % of 52-Week High
89.41%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
172.33%
-29.11%
Beta (5-Year)
1.394
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$12.40
200-day SMA
Buy
Level
$5.63
Bollinger Bands (100)
Buy
Level
4.6 - 10.78
Chaikin Money Flow
Buy
Level
4.1M
20-day SMA
Buy
Level
$12.40
Relative Strength Index (RSI14)
Buy
Level
59.46
ADX Line
Buy
Level
15.71
Williams %R
Neutral
Level
-47.8788
50-day SMA
Buy
Level
$10.38
MACD (12, 26)
Buy
Level
0.59
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
30.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8343)
Buy
CA Score
(Annual)
Level (-0.2027)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.2749)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Stock Forecast FAQ
In the current month, ETON has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ETON average analyst price target in the past 3 months is --.
-
Where Will Eton Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eton Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Eton Pharmaceuticals?
Analysts are divided on their view about Eton Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eton Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Eton Pharmaceuticals's Price Target?
The price target for Eton Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ETON A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eton Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ETON?
You can purchase shares of Eton Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eton Pharmaceuticals shares.
-
What Is The Eton Pharmaceuticals Share Price Today?
Eton Pharmaceuticals was last trading at $12.54 per share. This represents the most recent stock quote for Eton Pharmaceuticals. Yesterday, Eton Pharmaceuticals closed at $12.50 per share.
-
How To Buy Eton Pharmaceuticals Stock Online?
In order to purchase Eton Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
